RATIONALE: 5-Hydroxytryptamine (5-HT, serotonin) plays a major role in brain ontogeny. Disruption of 5-HT during early postnatal development produces lasting changes in rodent 'emotion-related' behaviors. Adverse effects of treatment with serotonin reuptake inhibitor (SRI) antidepressants have been reported in human adolescents. However, the long-term effects of chronic SRI treatment during adolescence in rodents remain unclear. OBJECTIVES: The objectives of the study are to assess the effects of fluoxetine treatment throughout the adolescent period in measures of fear-, anxiety- and stress-related endpoints in drug-free adults and to examine these effects in two genetic strains of mice differing in baseline stress- and anxiety-related behaviors and sensitivity to SRIs. MATERIALS AND METHODS: C57BL/6J and BALB/cJ mice received one of two fluoxetine doses for 4 weeks during adolescence (3-7 weeks old). A separate group of C57BL/6J and BALB/cJ mice received fluoxetine for 4 weeks during adulthood (8-12 weeks old). After a 3-week washout period, mice were tested for anxiety-like behaviors (novel open field, elevated plus-maze), fear conditioning and extinction, and stress-related responses to forced swim, as well as serotonin brain levels. RESULTS: Adolescent fluoxetine treatment did not increase adult measures of anxiety-, fear- or stress-related behaviors, or brain serotonin levels. The same duration of treatment in adulthood also had no effects on these measures when tested after a 3-week washout period. CONCLUSIONS: In clear contrast with emotion-related abnormalities caused by preadolescent fluoxetine treatment or genetic inactivation of fluoxetine's pharmacological target, the 5-HT transporter, fluoxetine treatment throughout mouse adolescence did not produce detectable, lasting abnormalities in either "high" or "low anxiety" inbred mouse strains.
RATIONALE: 5-Hydroxytryptamine (5-HT, serotonin) plays a major role in brain ontogeny. Disruption of 5-HT during early postnatal development produces lasting changes in rodent 'emotion-related' behaviors. Adverse effects of treatment with serotonin reuptake inhibitor (SRI) antidepressants have been reported in human adolescents. However, the long-term effects of chronic SRI treatment during adolescence in rodents remain unclear. OBJECTIVES: The objectives of the study are to assess the effects of fluoxetine treatment throughout the adolescent period in measures of fear-, anxiety- and stress-related endpoints in drug-free adults and to examine these effects in two genetic strains of mice differing in baseline stress- and anxiety-related behaviors and sensitivity to SRIs. MATERIALS AND METHODS: C57BL/6J and BALB/cJ mice received one of two fluoxetine doses for 4 weeks during adolescence (3-7 weeks old). A separate group of C57BL/6J and BALB/cJ mice received fluoxetine for 4 weeks during adulthood (8-12 weeks old). After a 3-week washout period, mice were tested for anxiety-like behaviors (novel open field, elevated plus-maze), fear conditioning and extinction, and stress-related responses to forced swim, as well as serotonin brain levels. RESULTS: Adolescent fluoxetine treatment did not increase adult measures of anxiety-, fear- or stress-related behaviors, or brain serotonin levels. The same duration of treatment in adulthood also had no effects on these measures when tested after a 3-week washout period. CONCLUSIONS: In clear contrast with emotion-related abnormalities caused by preadolescent fluoxetine treatment or genetic inactivation of fluoxetine's pharmacological target, the 5-HT transporter, fluoxetine treatment throughout mouse adolescence did not produce detectable, lasting abnormalities in either "high" or "low anxiety" inbred mouse strains.
Authors: C L Wellman; A Izquierdo; J E Garrett; K P Martin; J Carroll; R Millstein; K-P Lesch; D L Murphy; A Holmes Journal: J Neurosci Date: 2007-01-17 Impact factor: 6.167
Authors: Leanne M Fraser; Richard E Brown; Ahmed Hussin; Mara Fontana; Ashley Whittaker; Timothy P O'Leary; Lauren Lederle; Andrew Holmes; André Ramos Journal: Psychopharmacology (Berl) Date: 2010-05-08 Impact factor: 4.530
Authors: O Gunduz-Cinar; K P MacPherson; R Cinar; J Gamble-George; K Sugden; B Williams; G Godlewski; T S Ramikie; A X Gorka; S O Alapafuja; S P Nikas; A Makriyannis; R Poulton; S Patel; A R Hariri; A Caspi; T E Moffitt; G Kunos; A Holmes Journal: Mol Psychiatry Date: 2012-06-12 Impact factor: 15.992
Authors: Francisco J Flores-Ramirez; Lyonna F Parise; Jason B Alipio; Israel Garcia-Carachure; Samuel A Castillo; Minerva Rodriguez; Anapaula Themman; Omar Lira; Joshua Preciado-Piña; Sergio D Iñiguez Journal: J Affect Disord Date: 2019-02-19 Impact factor: 4.839
Authors: Iva Dincheva; Jianmin Yang; Anfei Li; Tina Marinic; Helena Freilingsdorf; Chienchun Huang; B J Casey; Barbara Hempstead; Charles E Glatt; Francis S Lee; Kevin G Bath; Deqiang Jing Journal: Am J Psychiatry Date: 2017-10-31 Impact factor: 18.112
Authors: Laura J Sittig; Choongwon Jeong; Emily Tixier; Joe Davis; Camila M Barrios-Camacho; Abraham A Palmer Journal: Mamm Genome Date: 2014-07-05 Impact factor: 2.957
Authors: Klaus V Wagner; Daria Marinescu; Jakob Hartmann; Xiao-Dong Wang; Christiana Labermaier; Sebastian H Scharf; Claudia Liebl; Manfred Uhr; Florian Holsboer; Marianne B Müller; Mathias V Schmidt Journal: Neuropsychopharmacology Date: 2012-08-08 Impact factor: 7.853